Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Eisai Inc. (LENVIMA)
(https://lenvima.com) 📸 Data Snapshot: May 30, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE LENVIMA® (lenvatinib) (https://lenvima.com)
LENVIMA® (lenvatinib)
Learn about LENVIMA® (lenvatinib), a prescription medicine that may help treat people with certain kinds of cancer.
NAV_HEADER_HEADING_REPEATED_BODY Thank You | LENVIMA.com (https://lenvima.com/thank-you-for-visiting/)
Thank You | LENVIMA.com
Thank you for visiting. Now going to a site with information about a treatment option for another type of cancer.
HEADING_REPEATED_FOOTER Thank You for Visiting LENVIMA.com (https://lenvima.com/thank-you/)
Thank You for Visiting LENVIMA.com
Thank you for visiting LENVIMA.com.
NAV_HEADER_HEADING_REPEATED_BODY RAI-R Differentiated Thyroid Cancer (DTC) (https://lenvima.com/differentiated-thyroid-cancer/)
RAI-R Differentiated Thyroid Cancer (DTC)
Learn about a prescription medicine that may help treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressing.
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://lenvima.com) LENVIMA® (lenvatinib)
[IMG: Your Path Forward With LENVIMA® (lenvatinib) Starts Now] [IMG: Your Path Forward With LENVIMA® (lenvatinib) Starts Now] Actor portrayal [H1] Your path forward with LENVIMA starts now Finding strength and courage in the face of cancer starts with learning about your treatment [H2] Which type of cancer treatment do you want to learn more about? Differentiated thyroid cancer (DTC) Advanced kidney cancer (RCC) as your first treatment* Advanced kidney cancer (RCC) after 1 previous treatment† Inoperable liver cancer (HCC) Advanced endometrial cancer* *Taken in combination with pembrolizumab. †Taken in combination with everolimus after one course of treatment with another anti-cancer medicine.
SUB-PAGE · THIN (https://lenvima.com/thank-you-for-visiting/) Thank You | LENVIMA.com
[H1] Thank you for visiting LENVIMA.com By continuing, you’ll be leaving Lenvima.com and going to a site with information about a treatment option for another type of cancer. Do you wish to continue? Continue Back
SUB-PAGE · THIN (https://lenvima.com/thank-you/) Thank You for Visiting LENVIMA.com
[H1] Thank you for visiting LENVIMA.com Eisai Inc. does not review the information contained on the following website for content, accuracy, or completeness. Use of and access to the information is subject to the terms, limitations, and conditions set by the website producer. Eisai Inc. makes no claims about the accuracy or any other aspect of the information contained on this website, nor does Eisai Inc. endorse this website. Do you wish to continue? Continue Back
SUB-PAGE (https://lenvima.com/differentiated-thyroid-cancer/) RAI-R Differentiated Thyroid Cancer (DTC)
[IMG: Differentiated Thyroid Cancer (DTC): You Are Not in This by Yourself] [IMG: Differentiated Thyroid Cancer (DTC): You Are Not in This by Yourself] Actor portrayal [H1] Differentiated thyroid cancer (DTC) You’re not in this by yourselfHow to take LENVIMA [IMG: See Results of a Clinical Trial of 392 Patients With Differentiated Thyroid Cancer (DTC) That Had Progressed and Could No Longer Be Treated With Radioactive Iodine (RAI)] [H2] LENVIMA clinical trial results LENVIMA was studied in a clinical trial of 392 people with DTC that had progressed and could no longer be treated with radioactive iodine (RAI).See the results [IMG: Side Effects of LENVIMA® (lenvatinib)] [H2] What you should know about certain side effects Side effects of LENVIMA [H2] Financial information and help Financial assistance programs are available to help appropriate patients access LENVIMA.Financial info and help [IMG: Getting Started on LENVIMA® (lenvatinib)] [H2] Getting started on LENVIMA Talk to your healthcare team to find out how you will receive LENVIMA.Receiving your prescription [H3] Prepare for what’s ahead with this helpful resource Your Guide to Taking LENVIMA for Differentiated Thyroid Cancer (DTC) Learn more about this type of cancer, how LENVIMA can help people with DTC, and what you can expect with treatment. Download in: English Spanish
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 0 |
| /thank-you-for-visiting/ | 0 | 0 |
| /thank-you/ | 1 | 0 |
| /differentiated-thyroid-cancer/ | 0 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
[
{
"@context": "https://schema.org",
"@type": "Drug",
"name": "Lenvima",
"nonProprietaryName": "lenvatinib",
"administrationRoute": "oral",
"dosageForm": "capsules",
"drugUnit": "10mg and 4mg capsule",
"manufacturer": "Eisai"
},
{
"@context": "https://schema.org",
"@type": "MedicalWebPage",
"url": "https://www.lenvima.com",
"audience": "patients"
}
]
/differentiated-thyroid-cancer/
[
{
"@context": "https://schema.org",
"@type": "Drug",
"name": "Lenvima",
"nonProprietaryName": "lenvatinib",
"administrationRoute": "oral",
"dosageForm": "capsules",
"drugUnit": "10mg and 4mg capsule",
"manufacturer": "Eisai"
},
{
"@context": "https://schema.org",
"@type": "MedicalWebPage",
"url": "https://www.lenvima.com/differentiated-thyroid-cancer",
"audience": "patients",
"name": "Differentiated Thyroid Cancer",
"about": [
"LENVIMA is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressing",
"For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer"
]
}
]
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: Eisai Inc. (LENVIMA) (lenvima.com)
A high-substance, low-BS pharmaceutical portal that prioritizes regulatory compliance over marketing fluff. Its only minor failures are a ‘ghost’ review flag in its metadata and the use of emotional cliches in its hero section.
Eliminate the ‘review_count: 1’ metadata from the ‘Thank You’ pages to remove the trust theatre flag. Replace the ‘Your path forward’ H1 with a more descriptive, clinical headline that references the specific indications. Add direct links to the published clinical trial results on ClinicalTrials.gov or PubMed to provide a complete proof path for the 392-patient study. Update the schema sameAs property to link directly to the FDA’s Drugs@FDA database entry for Lenvima.
The site is an exact match for the Pharma & Biotech industry, specifically focused on oncology. The presence of ‘Important Safety Information’ (ISI), specific cancer indications (DTC, RCC, HCC), and clinical trial enrollment numbers confirms its regulatory-heavy nature.
“The score of 13 was primarily driven by the 'Commodity Fingerprint' and 'Information Density' pillars. The emotional fluff in the hero section and the repeated regulatory template language added minor points, while a technical 'trust theatre' flag on a sub-page prevented a sub-10 score.”
This training module utilizes a snapshot of public data from Eisai Inc. (LENVIMA), captured on May 30, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Eisai Inc. (LENVIMA): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://lenvima.com to view the most current version of its content and learn from the source what this company is about and what it offers.